NDA 020576 · Recordati Rare
Cystadane
Betaine · Oral · Methylating Agent
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Oct 25, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
29
6 Phase 3, 3 recruiting
FAERS reports
1,045
656 serious, 74 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2026.
CYSTADANE ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are ( 1 ): Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 25, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- CYSTADANE · BETAINE 1GM/SCOOPFUL · FOR SOLUTION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Betaine" as an intervention, any sponsor and status, largest first.
- Quality of Life and Sjögren SyndromePivotal-lookingCompleted
Grupo de Investigação em Bioquímica e Biologia OralAcademic, hospital or other
NCT03578900 · 289 participants · Start Jan 1, 2013 · Primary completion Dec 31, 2014
Drug: Xeros; Citric Acid based Mouthwash · For: Xerostomia; Hyposalivation; Quality of Life and 1 more
- Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery PatientsPivotal-lookingTerminated
University of Alabama at BirminghamAcademic, hospital or other
NCT03401749 · 203 participants · Start Nov 1, 2018 · Primary completion Dec 1, 2020
Drug: Chlorhexidine Gluconate 2% Wipe · For: Surgical Site Infection
Sites: Birmingham, Alabama
- Acetic Acid 2% Solution for Skin UlcersPivotal-lookingRecruiting
Consorci Sanitari de l'Alt Penedès i GarrafAcademic, hospital or other
NCT06297967 · 104 participants (planned) · Start Apr 27, 2025 · Primary completion Mar 2028
Drug: Acetic Acid; Prontosan · For: Ulcer, Skin
Sites: Barcelona, Spain
- Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral DysbiosisPivotal-lookingCompleted
Mucosa Innovations, S.L.Industry
NCT05463484 · 100 participants · Start Jul 13, 2021 · Primary completion Feb 28, 2023
Drug: Test composition Saliactive® (olive product, betaine and xylitol); Placebo and 1 more · For: Oral Dysbiosis
Sites: Granada, Spain
- Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With InstillationPivotal-lookingCompleted
Georgetown UniversityAcademic, hospital or other
NCT01939145 · 100 participants · Start Sep 2013 · Primary completion Jul 2014
Drug: Normal saline · For: Wound Infection
Sites: Washington D.C., District of Columbia
University of California, San DiegoAcademic, hospital or other
NCT00348933 · 90 participants · Start Jul 2006 · Primary completion Feb 2010
Drug: Betaine; Creatine and 2 more · For: Angelman Syndrome; Nervous System Diseases
Sites: San Diego, California; Boston, Massachusetts; Greenwood, South Carolina · 4 sites in all
University of Nevada, Las VegasAcademic, hospital or other
NCT06309368 · 84 participants (planned) · Start Mar 14, 2024 · Primary completion Dec 2028
Drug: Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation · For: Surgical Site Infection; Wound Surgical; Colorectal Disorders
Sites: Las Vegas, Nevada
Universität des SaarlandesAcademic, hospital or other
NCT01095211 · 79 participants · Start Jan 2003 · Primary completion Sep 2005
Drug: B-vitamin complex · For: Cognitive Function; Metabolic Improvements
Sites: Sankt Ingbert, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use149
- overdose86
- vomiting81
- diarrhoea64
- product dose omission55
- nausea48
- seizure43
- product use issue41
- pneumonia39
- product dose omission issue39
- pyrexia39
- inappropriate schedule of product administration37
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 8 |
| 2012 | 24 |
| 2013 | 14 |
| 2014 | 35 |
| 2015 | 39 |
| 2016 | 85 |
| 2017 | 72 |
| 2018 | 83 |
| 2019 | 122 |
| 2020 | 123 |
| 2021 | 65 |
| 2022 | 84 |
| 2023 | 118 |
| 2024 | 64 |
| 2025 | 60 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cystadane (Betaine)
2024 spending
$1.1M
Beneficiaries
74
679 claims
Per beneficiary
$14,976
$4.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,490,250 |
| 2021 | $3,813,679 |
| 2022 | $4,191,100 |
| 2023 | $2,900,642 |
| 2024 | $1,108,241 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.
Hartiala JA, Han Y, Jia Q, et al. · Eur Heart J 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.
Morris AA, Kožich V, Santra S, et al. · J Inherit Metab Dis 2017 · Systematic Review
- Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations.
Zawieja E, Chmurzynska A · Ageing Res Rev 2025 · Systematic Review
- Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.
Morze J, Wittenbecher C, Schwingshackl L, et al. · Diabetes Care 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- Do "testosterone boosters" really increase serum total testosterone? A systematic review.
Morgado A, Tsampoukas G, Sokolakis I, et al. · Int J Impot Res 2024 · Systematic Review
- Genome-wide association study of selenium concentrations.
Cornelis MC, Fornage M, Foy M, et al. · Hum Mol Genet 2015 · Meta-Analysis, Research Support, N.I.H., Extramural
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.